A Survey of Icatibant in Pediatric Participants with Hereditary Angioedema

Phase

N/A

Condition

Hives (Urticaria)

Urticaria

Allergy

Treatment

Icatibant

Clinical Study ID

NCT05509569

TAK-667-4003

jRCT2031220292

Ages 2-17
All Genders

Study Summary

This study is a survey in Japan of Icatibant subcutaneous injection 30 mg syringe used to treat children or teenagers with acute attacks of hereditary angioedema (HAE). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.

The main aim of the study is to check for side effects related from Icatibant subcutaneous injection 30 mg syringe and to check if Icatibant subcutaneous injection 30 mg syringe improves acute attacks of HAE.

During the study, pediatric participants with HAE will take Icatibant subcutaneous injection 30mg syringe according to their clinic's standard practice. The study doctors will check for side effects from Icatibant subcutaneous injection 30 mg syringe for 3 months.

Eligibility Criteria

Inclusion

Inclusion Criteria:

All participants with HAE who are 2 to <18 years of age, treated with Icatibantsubcutaneous injection 30 mg syringe for the first time.

Exclusion

Exclusion Criteria:

Participants who have been treated with Icatibant subcutaneous injection 30 mgsyringe in clinical trials or transfer cases, and so on.

Study Design